Psychotropic drug classifications
Pro Research Analysisby 
Searched over 200M research papers
Traditional Psychotropic Drug Classifications: Indication-Based Systems
Historically, psychotropic drugs have been classified according to the World Health Organization’s Anatomical Therapeutic Chemical (ATC) system, which groups drugs based on the anatomical site of action and broad clinical indications. For example, drugs used in psychiatry are placed under the nervous system category, with further subdivisions such as antipsychotics, anxiolytics, and antidepressants. However, this system often fails to reflect the true pharmacological properties of drugs, as many medications are used for multiple conditions beyond their original indication. For instance, some antipsychotics are prescribed for bipolar disorder and treatment-resistant depression, while antidepressants are commonly used for anxiety disorders. This overlap can confuse both patients and clinicians, leading to misunderstandings about the drugs’ biological effects and intended uses 138.
Limitations of Indication-Based and Chemical Structure Classifications
The traditional classification systems, whether based on clinical effectiveness or chemical structure, have significant shortcomings. Drugs with similar clinical uses may have very different chemical structures, and the same drug can be effective for multiple psychiatric conditions. This lack of consistency makes indication-based and chemical structure classifications scientifically unsatisfactory and often outdated, as they do not keep pace with advances in pharmacology and clinical practice 4578.
Emergence of Pharmacologically Driven Classifications: Neuroscience-Based Nomenclature (NbN)
To address these issues, a new approach called the Neuroscience-based Nomenclature (NbN) has been developed. NbN classifies psychotropic drugs based on their pharmacological domains and mechanisms of action, rather than just their clinical indications. This system provides a clearer understanding of how drugs work at the molecular level, specifying the neurotransmitters, receptors, and systems they target. For example, instead of labeling a drug as an “antipsychotic,” NbN might describe it as a “D2, 5HT2 receptor antagonist,” offering more precise information about its action 1359+1 MORE.
NbN also includes additional dimensions such as approved indications, efficacy, side effects, practical notes, and neurobiology, making it a comprehensive tool for clinicians and researchers. This approach aims to improve communication, reduce stigma, and enhance treatment adherence by providing terminology that accurately reflects the rationale for drug selection 13910.
Objective and Automated Classification Methods
Research has also explored objective methods for classifying psychotropic drugs using biological markers, such as electrocorticographic (ECoG) activity in animal models and EEG power-spectrum variables in humans. These methods can distinguish between major drug classes—such as antidepressants, neuroleptics (antipsychotics), anxiolytics, and psychostimulants—based on their characteristic effects on brain activity. Automated classification systems using these biological data have shown high accuracy in correctly identifying drug classes and even recognizing subclasses within them 26.
Ongoing Challenges and the Need for Multidimensional Approaches
Despite advances, no single classification system is perfect. The complexity of psychotropic drugs, their diverse mechanisms, and overlapping clinical uses mean that a multidimensional, heuristic approach may be necessary. Combining pharmacological, clinical, and biological data can provide a more nuanced and practical taxonomy for both research and clinical practice 47.
Conclusion
Psychotropic drug classification has evolved from simple indication-based systems to more sophisticated, pharmacologically driven frameworks like the Neuroscience-based Nomenclature. While traditional systems are increasingly seen as outdated and confusing, newer approaches offer greater clarity by focusing on mechanisms of action and pharmacological profiles. Objective biological methods further enhance classification accuracy. However, the complexity of psychotropic drugs suggests that a flexible, multidimensional approach remains essential for effective communication and optimal patient care 1358+2 MORE.
Sources and full results
Most relevant research papers on this topic
A new nomenclature for classifying psychotropic drugs.
The Neuroscience-based Nomenclature (NbN) provides a more precise classification of psychotropic drugs, emphasizing pharmacology and molecular mechanisms of action, improving understanding and clinical use for clinicians and basic scientists.
A neuroscience-based nomenclature for psychotropic drugs
The neuroscience-based nomenclature (NbN) improves psychotropic drug classification by emphasizing pharmacological profile and mode of action, enabling better informed treatment decisions and downloadable apps.
DOI
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.
The Neuroscience-based Nomenclature (NbN) is a new system for classifying psychotropic drugs based on their pharmacological profile, supporting rational prescribing and potentially increasing drug adherence.
DOI